Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis Pharmaceuticals announced that the FDA has placed a partial clinical hold on three azenosertib monotherapy studies: Phase 1 ZN-c3-001, Phase 2 DENALI, and Phase 2 TETON due to two recent deaths in the DENALI study. Despite this setback, Zentalis remains optimistic about azenosertib's potential benefits, having treated over 500 patients with the drug. The company has completed enrollment for Cohort 1b of the DENALI study and plans to present the results later this year. Zentalis will also share findings from other studies and provide further updates following the resolution of the clinical hold. A conference call is scheduled for June 18, 8:00 am ET to discuss these developments.
Zentalis Pharmaceuticals announced on June 3, 2024, that its Compensation Committee granted new employees non-qualified stock options to purchase 20,000 shares under the 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). The exercise price is $11.40 per share, matching the closing price on the grant date. These options will vest over four years, with 25% vesting after one year and the rest monthly over the subsequent three years. The 2022 Inducement Plan aims to attract individuals new to Zentalis, promoting their long-term commitment to the company.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical firm, will participate in the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET. The company will host a fireside chat, with a live webcast and an archived recording accessible via their website. Zentalis specializes in developing small molecule therapeutics targeting cancer's fundamental biological pathways.
Zentalis Pharmaceuticals has appointed Dr. Luke Walker to its Board of Directors. Dr. Walker, currently the Chief Medical Officer at Harpoon Therapeutics, brings nearly 30 years of oncology and drug development experience, including successful product approvals. CEO Kimberly Blackwell highlighted his extensive expertise as pivotal for the advancement of Zentalis' pipeline, specifically azenosertib. Expected data readouts for azenosertib are anticipated throughout the remainder of 2024 and 2025, with regulatory submission planned for 2026. Dr. Walker's previous roles include VP of Clinical Development at Seagen and senior clinical roles at Cascadian Therapeutics.
Zentalis Pharmaceuticals announced the final results of its Phase 1 trial for azenosertib and gemcitabine in relapsed or refractory osteosarcoma patients, revealing a substantial improvement in event-free survival (EFS). The trial demonstrated a tripling of EFS at 18 weeks compared to historical data. Azenosertib was well tolerated, with thrombocytopenia and lymphopenia being the most common severe adverse events. The maximum tolerated dose was identified as 150 mg of azenosertib daily on a 5:2 schedule plus 800 mg/m2 of gemcitabine. The results support further investigation in a Phase 2 trial. The full data will be presented at the 2024 ASCO Annual Meeting.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer, will participate in the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, at 10:30 a.m. ET.
The event will be virtual, featuring a fireside chat with the management team. A live webcast and archived recording will be available on the company's website.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) reported its financial results for Q1 2024, showcasing progress in azenosertib clinical development plans and a strong cash position. The company highlighted upcoming milestones, corporate updates, and the projected cash runway into mid-2026. Azenosertib shows promise in various tumor types, with multiple data readouts expected in late 2024 and 2025, including results in gynecological cancers.
Zentalis Pharmaceuticals, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4), granting non-qualified stock options to three new employees. The options have an exercise price of $11.31 per share, a 10-year term, and will vest over four years.
Summary not available.
Summary not available.